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A B S T R A C T
Bordetella spp. are not normally included when
considering the opportunistic bacterial species
that are typically involved in respiratory tract
infections in individuals with cystic fibrosis (CF).
By using a combination of bacterial genotyping
and 16S rDNA sequencing, Bordetella spp. were
identified in cultures obtained from 43 individu-
als with CF. Most (n = 23) patients were infected
with Bordetella bronchiseptica ⁄ parapertussis; five
were infected with Bordetella hinzii, four with
Bordetella petrii, three with Bordetella avium, and
eight with unidentified Bordetella spp. Consider-
ation should be given to the presence of these
organisms in the evaluation of CF sputum
cultures.
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Cystic fibrosis (CF) is an autosomal recessive
disease, characterised by defective chloride ion
channels that result in multi-organ dysfunction,
most notably affecting the respiratory tract. The
alteration in the pulmonary environment is asso-
ciated with increased susceptibility to bacterial
infection. Recent advances in bacterial taxonomy
and improved microbial identification systems
have led to an increasing recognition of the
diversity of bacterial species involved in CF lung
infection. Many such species are opportunistic
human pathogens, some of which are rarely
found in other human infections [1]. Processing
of CF respiratory cultures therefore employs
selective media and focuses on detection of
uncommon human pathogens. In recent years,
the use of molecular methods (e.g., species-spe-
cific PCRs and assays based on identifying
restriction fragment length polymorphisms) has
complemented the diagnostic capacity of routine
phenotypic analyses. The present study describes
the use of molecular methods to identify Bordetella
spp. in respiratory tract cultures from 43 patients
with CF.
The 43 bacterial isolates included in the study
were recovered between June 2001 and June 2007
from sputum cultures obtained from 43 CF
patients receiving care in 19 treatment centres in
the USA. All isolates were sent to the Burkholderia
cepacia Research Laboratory and Repository
(BcRLR; University of Michigan, Ann Arbor,
Michigan, USA) for microbiological evaluation.
Reference strains comprised Achromobacter xylos-
oxidans ATCC 9220, Alcaligenes faecalis ATCC 337,
Alcaligenes faecalis subsp. faecalis LMG 1229T,
Alcaligenes sp. ATCC 21030, Bordetella avium
LMG 1852T, Bordetella bronchiseptica LMG 1232T,
Bordetella hinzii LMG 13500, Bordetella holmesii
LMG 15945T, Bordetella parapertussis LMG 14449T,
Bordetella pertussis LMG 14455T and Bordetella
trematum LMG 13506T. B. pertussis was grown on
Regan–Lowe charcoal agar (BBL, Franklin Lakes,
NJ, USA). All other bacterial isolates were grown
aerobically on plates containing Mueller–Hinton
broth (Becton Dickinson, Cockeysville, MD, USA)
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supplemented with agar 1.6% w ⁄ v, and were
incubated at 32C for 24–48 h. DNA was prepared
from bacterial cultures as described previously
[2]. A PCR targeting the 16S rDNA of A. xylosox-
idans was performed as described previously [3].
Bacterial genotyping was performed using rep-
PCR with the BOX A1R primer (BOX-PCR) as
described previously [4], with cluster analyses
performed by the unweighted pair-group method
with arithmetic averages (UPGMA). 16S rDNA
PCR amplification, sequencing and editing were
performed as described previously [2]. Isolates
were identified to the genus level if their edited
and assembled 16S rDNA sequence identity
compared with genera identified in the GenBank
database was >95%; isolates were tentatively
identified to the species level if the sequence
identity was ‡99%. All 16S rDNA sequences
determined in this study were deposited in
GenBank under accession numbers EU082134–
EU082176.
Only 11 (25%) of the 43 CF sputum culture
isolates were identified correctly as Bordetella spp.
by the referring laboratory, with the remainder
being identified as Achromobacter spp. (n = 11),
Burkholderia spp. (n = 2), or Pseudomonas spp.
(n = 1), or as ‘non-lactose-fermenting Gram-neg-
ative rod’ or ‘unidentified’ (n = 18). A variety of
commercial phenotypic test systems were used by
the referring laboratories (Table 1).
The 43 isolates were analysed at the BcRLR by
using a range of species-specific 16S rDNA PCR
assays for CF-related bacterial species, including
species of Pseudomonas, Stenotrophomonas, Burk-
holderia, Ralstonia, Pandoraea and Achromobacter
[2,3,5–11]. All PCR assays were negative, except
that 33 (77%) of the 43 isolates were positive
according to a PCR assay designed to be specific
for A. xylosoxidans [3]. However, cluster analysis
of DNA profiles generated by BOX-PCR placed
these 33 isolates (as well as the remaining ten
isolates) in a cluster distinct from that formed by
all other Achromobacter strains (including refer-
ence strains) in the BcRLR’s collection (results not
shown). 16S rDNA sequence analysis of the 43
isolates revealed that 23 were B. bronchisepti-
ca ⁄ parapertussis, five were B. hinzii, four were
Bordetella petrii, three were B. avium, and eight
were unidentified Bordetella spp.
Although Bordetella spp. are not normally con-
sidered when evaluating CF sputum cultures,
occasional case reports have described the recov-
ery of some species, including B. hinzii [12,13],
B. bronchiseptica [14,15] and B. petrii [16], from
individual CF patients. To our knowledge, B. avi-
um has not been identified previously in CF
sputum cultures.
The frequency with which these species are
involved in pulmonary infection in CF patients is
unclear. During the 6-year period of this study,
sputum isolates were analysed from 874 CF
patients (receiving care in 183 treatment centres),
with Bordetella strains isolated from 43 (5%)
patients. Although this rate is comparable to that
of some other CF pathogens, including Burkholde-
ria spp., there was a potential bias in the sample
set in that care centres are more likely to refer
‘atypical’ isolates for which the species identifi-
cation may be in question. The presence of other,
more common, CF-related pathogens, including
Achromobacter, Burkholderia, Pseudomonas and
Stenotrophomonas, was detected in only 13 (30%)
of the 43 patients. This raises the possibility that
the recovery of Bordetella may be influenced by
the presence of other species that might ordinarily
overgrow Bordetella in culture. If this is the case,




Microscana Rapid NFb Vitekc API NFc PASCOd Biocheme N ⁄ Af
Bordetella spp. (n = 11)f 3 2 3 1 1
Achromobacter spp. (n = 11) 3 3 1 2 2
Burkholderia spp. (n = 2) 1 1
Pseudomonas spp. (n = 1) 1
NLFGNR (n = 18) 2 2 6 1 1 3 3
N ⁄ A, method not specified; NLFGNR, non-lactose-fermenting Gram-negative rod.
aDade Behring Inc., West Sacramento, CA, USA.
bRemel Inc., Norcross, GA, USA.
cbioMérieux, Durham, NC, USA.
dPASCO Laboratories, Wheat Ridge, CO, USA.
eShort biochemical battery.
fOne isolate was identified by the referring laboratory as Bordetella by 16S rDNA sequence analysis.
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the prevalence of Bordetella within the CF popu-
lation may well be underestimated. However, a
prospective study of a non-biased sample set
would be necessary to reach firm conclusions in
this respect.
The role that these species may play in the
progression of CF pulmonary disease is also
unclear. Bordetella-infected patients ranged in age
from 3 to 53 years, with 25 (58%) being aged
<18 years. Only a single Bordetella isolate was
identified among sputum culture isolates obtained
serially for 41 of the 43 patients, suggesting
transient colonisation with Bordetella. However,
chronic infection is possible, with serial cultures
from two patients yielding the same Bordetella
strain for periods of 2 years (B. petrii) and 5 years
(unidentified Bordetella sp.), respectively. No data
were available concerning antimicrobial therapy
given to these two patients during these periods.
The analysis revealed a high rate of misiden-
tification of Bordetella spp. according to commer-
cially available microbial identification systems,
with 75% of the isolates (from 11 centres) being
misidentified by the referring laboratory (Table 1).
Misidentification of Bordetella as Achromobacter
was particularly common, perhaps because of
the incomplete and changing taxonomy of these
two phylogenetically closely related genera.
Indeed, a PCR assay designed to be specific for
A. xylosoxidans on the basis of then available 16S
rDNA sequence data [3] was positive for several
isolates that were identified subsequently as
Bordetella spp. It is noteworthy that cluster anal-
ysis of 16S rDNA sequences of the eight isolates
identified as ‘unclassified Bordetella’ suggested the
presence of at least four distinct, potentially
novel, Bordetella spp. (data not shown).
In summary, this report describes the largest
set of CF patients from whom Bordetella spp. have
been identified, including the probable first report
of B. avium infection in this patient population.
Most isolates were identified incorrectly in initial
testing by the referring laboratories, suggesting
that further consideration should be given to the
possible presence of Bordetella spp. in the evalu-
ation of CF sputum culture.
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